Chuck Royce acquired 1.16 Million Haemonetics shares worth $81.8 Million. That's 0.88% of their equity portfolio (6th largest holding). The investor owns 2.52% of the outstanding Haemonetics stock. The first Haemonetics trade was made in Q2 2013. Since then Chuck Royce bought shares nineteen more times and sold shares on ten occasions. The investor's estimated purchase price is $95.5 Million, resulting in a loss of 14%.